Biocon developing 20 biosimilar products for global markets
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.
biosimilar
January 2022
December 2021
Biocon wins US patent battle against Sanofi on insulin biosimilar
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
